Similarly, tumor alteration burden, PD-L1 expression, and CTL infiltration showed a modest correlation with 12-month OS (AUC, 0.55 for tumor alteration burden, 0.62 for PD-L1 expression, and 0.60 for CTL infiltration) and with 20-month OS (AUC, 0.61 for tumor alteration burden, 0.62 for PD-L1 expression, and 0.59 for CTL infiltration) in the IMvigor210 trial. The gene discussed is CD274; the disease is neoplasm.